Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis <scp>B</scp> vaccine in inflammatory bowel disease patients

Andrade, Patrícia; Santos-Antunes, João; Rodrigues, Susana; Lopes, Susana; Macedo, Guilherme

doi:10.1111/jgh.13001

Cited by 56 publications

(56 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most probable explanation for this difference is the fact that children are likely to be treated with immunomodulators and/or biologicals for a much shorter time than adults. As an example, the disease duration, defined as the time from the date of IBD diagnosis to the date of the study entry, was 13 months in our study, 3.5 years in the Urganci et al study, and 5.2 years in the Moses et al study, compared to 5.9 years [16], 7.9 years [17], and 10.3 years in adult studies [18].…”

Section: Discussionmentioning

confidence: 45%

Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease

Baranowska-Nowak¹,

Iwańczak

Szczepanik

et al. 2020

cejoi

View full text Add to dashboard Cite

Aim of the study: to evaluate the immune response rate in children with inflammatory bowel disease (IBD) who received the full hepatitis B vaccination course in infancy. we also evaluated rates of response to booster doses. Material and methods: participants were 1-to 18-year-old children with IBD, who received 3 doses of the hepatitis B vaccine in infancy. the study subjects were on no immunosuppressive therapy, on immunomodulators, on biological therapy, or received combo therapy. anti-hepatitis B surface antibody (anti-hBs) level ≥ 10 mIu/ml was considered to be seroprotective. patients with anti-hBs level < 10 mIu/ml received 1 or 3 doses of hepatitis B vaccine, and their post-vaccination anti-hBs levels were evaluated. Results: In total, we included 157 subjects, with a median age of 14.5 years. anti-hBs levels ≥ 10 miu/ml were found in 84/157 (53.5%) patients and were not associated with age (p = 0.3), sex (p = 0.7), or IBD type (p = 0.9). there was no significant difference in the rate of seroconversion between IBD patients treated with no immunosuppressive drugs, immunomodulators, biologicals, and combo therapy (30.4% vs. 39.3% vs. 2.7% vs. 7.1%, respectively, p = 0.3). after the first and third dose of booster vaccine, anti-hBs levels ≥ 10 mIu/ml were as follows: 92% and 100%, respectively. Conclusions: the immune response in children with IBD, who received the full series of hepatitis B vaccinations in infancy was inadequate and did not depend on the type of therapy. the booster dose(s) of vaccine could help to protect this group of patients from hepatitis B virus.

show abstract

Section: Discussionmentioning

confidence: 45%

Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease

Baranowska-Nowak¹,

Iwańczak

Szczepanik

et al. 2020

cejoi

View full text Add to dashboard Cite

show abstract

“…[12] Review: [126] Unter Therapie Nachweis einer reduzierten Immunantwort nach Influenza- [127,128], Pneumokokken (PPSV23)- [129] und Hepatitis B-Impfung [130], insbesondere bei Kombination mit Thiopurinen [127]; bei Hepatitis B-Impfung vor Therapiebeginn adäquate Immunantwort [130]. [151] Reduzierte humorale Immunantwort auf Pneumokokken(PPSV23)-Impfstoff [151] (FI-A), aber keine Reduktion der T-Zell-abhängigen Immunantwort auf PCV13-bzw.…”

Section: Bekanntmachungen -Amtliche Mitteilungenunclassified

Impfen bei Immundefizienz

Wagner

Assmus

Arendt

et al. 2019

Bundesgesundheitsbl

122

View full text Add to dashboard Cite

show abstract

“…Der Zeitpunkt der Impfung innerhalb eines regelmäßigen anti-TNF-α-Therapiezyklus beeinflusst das Ansprechen auf eine Influenza-Impfung nicht [158]. Bezüglich einer Hepatitis B ist das Ansprechen bei Patienten mit CED insbesondere unter einer anti-TNF-α-Therapie reduziert, wobei das Ansprechen junger Patienten zu Beginn der anti-TNF-α-Therapie und als Monotherapie noch am günstigsten ist [82,159]. In diesem Zusammenhang ist darauf hinzuweisen, dass trotz Ansprechens auf die Impfung nach 12 Monaten bei bis zu 21 % mit einem Verlust des Impfschutzes gerechnet werden muss, weshalb sich die Überwachung des Impftiters empfiehlt [160].…”

Section: Totimpfungenunclassified

Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

Miehsler¹,

Dejaco

Gröchenig³

et al. 2018

Z Gastroenterol

View full text Add to dashboard Cite

Anti-TNFα-antibodies have revolutionized the therapy of inflammatory bowel diseases and other immune-mediated inflammatory diseases. Due to the increasing application of these substances, the Working Group of Inflammatory Bowel Diseases of the Austrian Association of Gastroenterology and Hepatology intended to update their consensus report on the safe use of Infliximab (published in 2010) and to enlarge its scope to cover all anti-TNFα-antibodies. The present consensus report summarizes the current evidence on the safe use of anti-TNFα-antibodies and covers the following topics: general risk of infection, bacterial infections (i. e., Clostridium difficile, Tuberculosis, food hygiene), Pneumocystis jiroveci, viral infections (i. e., Hepatitis B, Hepatitis C, HIV, CMV, VZV), vaccination in general and recommendation for vaccines, gastrointestinal aspects (i. e., perianal fistula, abdominal fistula, intestinal strictures, stenosis and bowel obstruction), dermatologic aspects (skin malignancies, eczema-like drug-related skin eruption), infusion reactions and immunogenicity, demyelinating diseases, hepatotoxicity, haematotoxicity, congestive heart failure, risk and history of malignancies, and pregnancy and breast feeding. For practical reasons, the relevant aspects are summarized in a checklist which is divided into two parts: issues to be addressed before therapy and issues to be addressed during therapy.

show abstract

Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients

Abstract: The response rate to the standard HBV vaccination in IBD patients is low mainly in those treated with infliximab and/or azathioprine.

Cited by 56 publications

References 36 publications

Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease

Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease

Impfen bei Immundefizienz

Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

Contact Info

Product

Resources

About